Aldeyra Therapeutics, Inc. (ALDX) Financial Statements (2025 and earlier)

Company Profile

Business Address 131 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:46,624,180 29,881,520229,790,98977,858,31144,425,830
Cash and cash equivalent    229,790,98977,858,31144,425,830
Short-term investments46,624,180 29,881,520  28,938,545
Other undisclosed cash, cash equivalents, and short-term investments      (28,938,545)
Prepaid expense408,091340,388    
Other undisclosed current assets57,040,207147,469,945151,141,5932,961,7815,200,95730,742,995
Total current assets:104,072,478147,810,333181,023,113232,752,77083,059,26875,168,825
Noncurrent Assets
Operating lease, right-of-use asset266,955510,814249,265351,863233,310201,007
Property, plant and equipment  5,76419,27932,48759,925148,449
Deferred costs 267,261     
Total noncurrent assets:534,216516,578268,544384,350293,235349,456
TOTAL ASSETS:104,606,694148,326,911181,291,657233,137,12083,352,50375,518,281
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,298,8206,874,52114,199,51011,543,0558,516,40312,681,424
Accounts payable180,4531,338,057133,6251,019,702381,638808,302
Accrued liabilities12,118,3675,536,46414,065,88510,523,3538,134,76511,873,122
Deferred revenue 6,000,000     
Debt31,37215,146,546911,763 3,659,776226,328
Other undisclosed current liabilities271,631239,183249,265229,607233,310 
Total current liabilities:18,601,82322,260,25015,360,53811,772,66212,409,48912,907,752
Noncurrent Liabilities
Long-term debt and lease obligation15,000,00015,000,00014,923,09015,628,93511,434,45614,528,212
Long-term debt, excluding current maturities15,000,00015,000,00014,923,09015,503,70311,434,45614,528,212
Liabilities, other than long-term debt 271,631    
Operating lease, liability 271,631 125,232  
Other undisclosed noncurrent liabilities (9,000,000) (125,232)  
Total noncurrent liabilities:15,000,0006,271,63114,923,09015,628,93511,434,45614,528,212
Total liabilities:33,601,82328,531,88130,283,62827,401,59723,843,94527,435,964
Equity
Equity, attributable to parent71,004,871119,795,030151,008,029205,735,52359,508,55848,082,317
Common stock59,64859,19658,56058,08138,66728,657
Additional paid in capital521,018,373513,994,982507,770,045500,369,444296,385,619247,409,793
Accumulated other comprehensive income (loss)37,442 (103,938)  5,866
Accumulated deficit(450,110,592)(394,259,148)(356,716,638)(294,692,002)(236,915,728)(199,361,999)
Total equity:71,004,871119,795,030151,008,029205,735,52359,508,55848,082,317
TOTAL LIABILITIES AND EQUITY:104,606,694148,326,911181,291,657233,137,12083,352,50375,518,281

Income Statement (P&L) (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(60,117,032)(42,794,083)(62,679,987)(56,219,536)(34,666,755)(56,506,553)
Other undisclosed operating loss     (1,754,265)(6,567,754)
Operating loss:(60,117,032)(42,794,083)(62,679,987)(56,219,536)(36,421,020)(63,074,307)
Nonoperating income (expense)4,265,5885,251,573655,351(1,556,738)(1,611,974)937,503
Investment income, nonoperating6,191,8297,323,0082,349,449185,363292,2241,541,349
Interest and debt expense(1,926,241)(2,071,435)(1,694,098)(1,742,101)(1,904,198)(603,846)
Loss from continuing operations before equity method investments, income taxes:(57,777,685)(39,613,945)(63,718,734)(59,518,375)(39,937,192)(62,740,650)
Other undisclosed income from continuing operations before income taxes    1,742,1011,904,198603,846
Loss from continuing operations before income taxes:(57,777,685)(39,613,945)(63,718,734)(57,776,274)(38,032,994)(62,136,804)
Income tax expense (benefit) (1,000)   479,2651,309,973
Other undisclosed loss from continuing operations      
Loss from continuing operations:(57,778,685)(39,613,945)(63,718,734)(57,776,274)(37,553,729)(60,826,831)
Loss before gain (loss) on sale of properties:(57,776,274)(37,553,729)(60,826,831)
Other undisclosed net income1,927,2412,071,4351,694,098   
Net loss:(55,851,444)(37,542,510)(62,024,636)(57,776,274)(37,553,729)(60,826,831)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(55,851,444)(37,542,510)(62,024,636)(57,776,274)(37,553,729)(60,826,831)

Comprehensive Income (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(55,851,444)(37,542,510)(62,024,636)(57,776,274)(37,553,729)(60,826,831)
Other comprehensive income (loss)  103,938(103,938) (5,866)15,090
Comprehensive loss:(55,851,444)(37,438,572)(62,128,574)(57,776,274)(37,559,595)(60,811,741)
Other undisclosed comprehensive income, net of tax, attributable to parent37,442     
Comprehensive loss, net of tax, attributable to parent:(55,814,002)(37,438,572)(62,128,574)(57,776,274)(37,559,595)(60,811,741)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: